Cellectis

Regulatory Filings • Jan 13, 2015

PRESS RELEASE

Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma

Paris, January 13, 2015 - Cellectis SA (Alternext: ALCLS.PA) announces that it has entered into an exclusive license agreement with The Ohio State University, through the Ohio State Innovation Foundation, to develop and commercialize chimeric antigen receptor (CAR) technology targeting multiple myeloma cells.

The CAR technology licensed to Cellectis is related to CS1, an antigen that is over-expressed in multiple myeloma cells. Cellectis intends to pursue the development of a CS1 CAR T-cell program for this targeted indication.

Multiple myeloma is the second most common type of blood cancer with a five-year survival rate of 45%. This cancer represents a major unmet medical need.

André Choulika, Chief Executive Officer and Chairman of Cellectis stated "This agreement aligns with our CAR T-cell development strategy to bring innovative therapies to patients with cancer. We are pleased to have entered into this license agreement with Ohio State University since it is a major research center with unique and outstanding expertise in multiple myeloma."

Cellectis is currently developing three proprietary allogeneic CAR T-cell product candidates in the field of liquid tumors, targeting CD123 in acute myeloid leukemia, as well as CD38 and CS1 for multiple myeloma. Cellectis aims to file in 2015 an application for a Clinical Trial Authorization for its allogeneic UCART191 product candidate, which targets CD19 in acute lymphoblastic leukemia and chronic lymphocytic leukemia.

For further information, please contact:

Cellectis Jennifer Moore Phone: +33 (0)1 81 69 16 00 e-mail: media@cellectis.com

BMC Communications - New York City Brad Miles Phone: 646-513-3125 e-mail: bmiles@bmccommunications.com

About Cellectis

Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation

1 Under exclusive option for Servier

PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS).

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.